Good Products, a leading provider of Enterprise Content Management (ECM) solutions for the pharmaceutical and biopharmaceutical industries, announces the availability of its new Validation Project Management tool ValMan.
Good Products Launches ValMan™to Facilitate Validation Project Management
(12 August, 2008) Good Products, a leading provider of Enterprise Content Management (ECM) solutions for the pharmaceutical and biopharmaceutical industries, announces the availability of its new Validation Project Management tool ValMan™. This unique software helps life sciences organizations to store and manage validation protocols and test plans, enabling compliance with the strict regulations governing the industry. ValMan™ is available as part of the g-docs™ suite which is designed to streamline document management. A free of charge demo can be accessed via ValMan@goodproductsEU.com
Within the life sciences industry, multiple validation systems have traditionally been used to manage validation documents and projects, with individual templates being created for each project. Companies are now finding these processes extremely time-consuming and costly, and are looking for more streamlined and cohesive alternatives. Good Products has developed ValMan™ to provide a cost-effective, practical and complete validation project management system, and as the regulations and requirements change then protocols, templates and master plans are updated automatically.
ValMan™ enhances Good Products’ existing portfolio of eDMS solutions, which offer organizations regulatory-compliant, effective and easy-to-use methods of tracking documents and managing approvals. ValMan™ allows users to manage multiple validation projects in a clear and organized format, with the status of each of the products visible on a high level portfolio page.
The ValMan™ software tool allows documents and activities for specific projects to be stored in separate secure areas, while a set of predetermined workflow templates facilitates effective project management. Version control of all documents is carried out within ValMan™ and approved documents are published to a separate library for added user convenience. Product training is minimal as users are already familiar with the web browser environment of the g-docs™ platform and once ValMan™ is implemented, administrators control the ability to configure future libraries, templates and workflows.
ValMan™ customers can choose from a database of over 5,000 validation template documents covering facilities, cleaning, manufacturing equipment, laboratory equipment and computerized systems for biopharma, laboratory and clinical organizations to pre-populate their validation document libraries. ValMan™ also contains pre-configured project workflows, although companies’ existing templates, responsibility matrices, protocol review and approval workflows can also be entered quickly into the system. Within ValMan™, documents are stored on the g-docs™ MOSS 2007 platform and can be easily integrated with existing software systems, such as training management and learning management systems. Electronic documents and protocol deviation forms can be easily digitally signed using the CoSign® digital signature solution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.